Scarica l'app Stockscreener
1.25
58.23%
0.46
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Merger Talk: Will AIM ImmunoTech Inc. stock outperform global peersEarnings Beat & Verified Chart Pattern Trade Signals - mfd.ru
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - Bitget
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
Pancreatic cancer drug strategy: AIM ImmunoTech CEO in Feb. 19 live webcast - Stock Titan
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech launches rights offering to raise $12 million - Intellectia AI
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - 富途牛牛
Pancreatic cancer focus: AIM ImmunoTech CEO joins Webull live webinar - Stock Titan
AIM ImmunoTech Eyes $12M Funding Boost with Rights Offering - timothysykes.com
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Announces Positive Phase 2 Trial Results fo - GuruFocus
AIM ImmunoTech’s $12M Rights Offering: Implications and Prospects - StocksToTrade
Why Is AIM ImmunoTech Stock Up Today? - TipRanks
AIM ImmunoTech Rights Offering Targets $12 Million Boost - timothysykes.com
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | AIM Stock News - Longbridge
AIM ImmunoTech Provides Interim DURIPANC Clinical Progress Update - TipRanks
AIM ImmunoTech Inc Provides Interim Update on DURIPANC Study - TradingView
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewswire
Experimental drug combo shows survival promise in pancreatic cancer trial - Stock Titan
Pricey healthcare stocks with halting momentumlow momentum and high valuation (AIM:NYSE) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering - The Manila Times
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewswire
AIM ImmunoTech Stock Trading Halted, Pending Material News Release - marketscreener.com
AIM ImmunoTech Adjusts Class E Warrant Terms After Dividend - TipRanks
AIM ImmunoTech Inc Modifies Class E and F Warrants - TradingView
Why AIM ImmunoTech Inc. (HXB) stock gets analyst attentionSupport Zone Identification & The Smart Money Is Buying These Picks - bollywoodhelpline.com
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
AIM ImmunoTech Highlights Ampligen Development Risks and Plans - The Globe and Mail
Trend Recap: How AIM ImmunoTech Inc stock compares with tech leadersDollar Strength & Entry Point Confirmation Signals - Bộ Nội Vụ
AIM ImmunoTech (NYSEAMERICAN:AIM) Upgraded at Zacks Research - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Rate Cut: Is AIM ImmunoTech Inc HXB stock undervalued after correctionMarket Activity Summary & Free Expert Verified Stock Movement Alerts - Bộ Nội Vụ
AIM ImmunoTech Inc.: - MarketScreener
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AIM ImmunoTech (NYSEAMERICAN:AIM) Shares to Split on Friday, January 9th - Defense World
AIM ImmunoTech: One Shr for Every 1,000 Shrs or for Every Outstanding Option or Warrant Having a Right to Stk Dividends >AIM - 富途牛牛
AIM ImmunoTech Announces Stock Dividend - The Manila Times
AIM ImmunoTech to give extra shares to investors via stock dividend - Stock Titan
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
Published on: 2025-12-21 18:10:19 - Улправда
Why AIM ImmunoTech Inc. (HXB) stock is a must watch tickerPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - Улправда
How AIM ImmunoTech Inc. (HXB) stock performs during market turbulenceJuly 2025 Recap & Trade Opportunity Analysis Reports - DonanımHaber
Will AIM ImmunoTech Inc. stock benefit from sector leadershipRate Cut & Real-Time Price Movement Reports - DonanımHaber
Published on: 2025-12-19 13:37:56 - Улправда
AIM ImmunoTech Completes 2025 Annual Stockholder Meeting - TipRanks
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):